Abbott Laboratories
ABT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -2.05 | -36.74 | 0.61 |
| FCF Yield | 3.24% | 2.65% | 4.05% | 3.46% |
| EV / EBITDA | 18.79 | 18.84 | 16.87 | 21.32 |
| Quality | ||||
| ROIC | 18.90% | 9.10% | 11.36% | 12.56% |
| Gross Margin | 50.83% | 49.96% | 51.14% | 53.89% |
| Cash Conversion Ratio | 0.64 | 1.27 | 1.38 | 1.49 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.32% | -2.35% | 8.05% | 10.52% |
| Free Cash Flow Growth | 25.54% | -35.17% | -9.76% | 51.08% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | 0.85 | 0.68 | 0.78 |
| Interest Coverage | 11.32 | 9.22 | 26.55 | 22.44 |
| Efficiency | ||||
| Inventory Turnover | 3.33 | 3.06 | 3.46 | 3.85 |
| Cash Conversion Cycle | 95.63 | 101.11 | 78.79 | 68.73 |